View : 606 Download: 190

Full metadata record

DC Field Value Language
dc.contributor.author이진화*
dc.date.accessioned2018-12-07T16:30:14Z-
dc.date.available2018-12-07T16:30:14Z-
dc.date.issued2017*
dc.identifier.issn1465-993X*
dc.identifier.otherOAK-21827*
dc.identifier.urihttps://dspace.ewha.ac.kr/handle/2015.oak/247245-
dc.description.abstractBACKGROUND: The effects of corticosteroid-based therapy in patients with idiopathic nonspecific interstitial pneumonia (iNSIP), and factors affecting treatment outcome, are not fully understood. We aimed to investigate the long-term treatment response and factors affecting the treatment outcome in iNSIP patients from a multi-center study in Korea.METHODS: The Korean interstitial lung disease (ILD) Study Group surveyed ILD patients from 2003 to 2007. Patients were divided into two groups to compare the treatment response: response group (forced vital capacity (FVC) improves ≥10% after 1 year) and non-response group (FVC <10%). Factors affecting treatment response were evaluated by multivariate logistic regression analysis.RESULTS: A total of 261 patients with iNSIP were enrolled, and 95 patients were followed-up for more than 1 year. Corticosteroid treatment was performed in 86 patients. The treatment group showed a significant improvement in lung function after 1-year: FVC, 10.0%; forced expiratory volume (FEV1), 9.8%; diffusing capacity of the lung for carbon monoxide (DLco), 8.4% (p < 0.001). Sero-negative anti-nuclear antibody (ANA) was significantly related with lung function improvement. Sero-positivity ANA was significantly lower in the response group (p = 0.013), compared to that in the non-response group. A shorter duration of respiratory symptoms at diagnosis was significantly associated with a good response to treatment (p = 0.018).CONCLUSION: Treatment with corticosteroids and/or immunosuppressants improved lung function in iNSIP patients, which was more pronounced in sero-negative ANA and shorter symptom duration patients. These findings suggest that early treatment should be considered in iNSIP patients, even in an early disease stage.*
dc.languageEnglish*
dc.subjectNon-specific interstitial pneumonia*
dc.subjectPulmonary lung function*
dc.subjectTreatment*
dc.titleFactors affecting treatment outcome in patients with idiopathic nonspecific interstitial pneumonia: a nationwide cohort study*
dc.typeArticle*
dc.relation.issue1*
dc.relation.volume18*
dc.relation.indexSCIE*
dc.relation.indexSCOPUS*
dc.relation.startpage204*
dc.relation.journaltitleRespiratory research*
dc.identifier.doi10.1186/s12931-017-0686-7*
dc.identifier.wosidWOS:000417509400002*
dc.identifier.scopusid2-s2.0-85050662015*
dc.author.googleLee S.H.*
dc.author.googlePark M.S.*
dc.author.googleKim S.Y.*
dc.author.googleKim D.S.*
dc.author.googleKim Y.W.*
dc.author.googleChung M.P.*
dc.author.googleUh S.T.*
dc.author.googlePark C.S.*
dc.author.googlePark S.W.*
dc.author.googleJeong S.H.*
dc.author.googlePark Y.B.*
dc.author.googleLee H.L.*
dc.author.googleShin J.W.*
dc.author.googleLee E.J.*
dc.author.googleLee J.H.*
dc.author.googleJegal Y.*
dc.author.googleLee H.K.*
dc.author.googleKim Y.H.*
dc.author.googleSong J.W.*
dc.author.googlePark J.S.*
dc.contributor.scopusid이진화(56646645800;58376333800)*
dc.date.modifydate20240419140935*


qrcode

BROWSE